Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PIII Stock Forecast 2026-2027
$11.69
Current Price
$2.38B
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PIII Price Targets
+19.8%
To High Target of $14.00
+19.8%
To Median Target of $14.00
+19.8%
To Low Target of $14.00
PIII Price Momentum
-6.8%
1 Week Change
+3.5%
1 Month Change
+79.8%
1 Year Change
+235.0%
Year-to-Date Change
-30.8%
From 52W High of $16.89
+669.1%
From 52W Low of $1.52
📊 TOP ANALYST CALLS
Did PIII Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if P3 Health is one of their latest high-conviction picks.
Latest PIII Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, PIII has a neutral consensus with a median price target of $14.00 (ranging from $14.00 to $14.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $11.69, the median forecast implies a 19.8% upside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ryan Langston at TD Cowen, projecting a 19.8% upside. Conversely, the most conservative target is provided by Ryan Langston at TD Cowen, suggesting a 19.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PIII Analyst Ratings
1
Buy
1
Hold
0
Sell
PIII Price Target Range
Low
$14.00
Average
$14.00
High
$14.00
Current: $11.69
Latest PIII Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PIII.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 22, 2026 | TD Cowen | Ryan Langston | Hold | Maintains | $14.00 |
| May 15, 2026 | Lake Street | Ben Haynor | Buy | Maintains | $14.00 |
| Apr 2, 2026 | TD Cowen | Hold | Maintains | $N/A | |
| Mar 27, 2026 | Lake Street | Buy | Maintains | $N/A | |
| Nov 17, 2025 | Lake Street | Buy | Maintains | $N/A | |
| Aug 28, 2025 | Lake Street | Ben Haynor | Buy | Assumes | $20.00 |
| Apr 21, 2025 | Lake Street | Buy | Maintains | $N/A | |
| Nov 20, 2024 | TD Cowen | Hold | Maintains | $N/A | |
| Apr 1, 2024 | BTIG | Neutral | Downgrade | $N/A | |
| Mar 14, 2024 | Lake Street | Buy | Maintains | $N/A | |
| Sep 1, 2023 | BTIG | Buy | Initiates | $N/A | |
| Jun 30, 2023 | TD Cowen | Market Perform | Initiates | $N/A | |
| Jan 4, 2022 | William Blair | Outperform | Initiates | $N/A |
P3 Health Partners Inc. (PIII) Competitors
The following stocks are similar to P3 Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
P3 Health Partners Inc. (PIII) Financial Data
P3 Health Partners Inc. has a market capitalization of $2.38B with a P/E ratio of -0.3x. The company generates $1.46B in trailing twelve-month revenue with a -10.1% profit margin.
Revenue growth is +3.8% quarter-over-quarter, while maintaining an operating margin of -40.0% and return on equity of -6,952.6%.
Valuation Metrics
Market Cap
$2.38B
Enterprise Value
$317.56M
P/E Ratio
-0.3x
PEG Ratio
0.0x
Price/Sales
1.7x
Growth & Margins
Revenue Growth (YoY)
+3.8%
Gross Margin
N/A
Operating Margin
-40.0%
Net Margin
-10.1%
EPS Growth
+3.5%
Financial Health
Cash/Price Ratio
+65.0%
Current Ratio
0.2x
Debt/Equity
-2.2x
ROE
-6,952.6%
ROA
-23.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
P3 Health Partners Inc. (PIII) Business Model
About P3 Health Partners Inc.
What They Do
Provides value-based healthcare services.
Business Model
The company operates a population health management model that partners with healthcare providers to enhance care coordination for Medicare-eligible patients. It generates revenue by offering support services that help clinicians improve patient outcomes and reduce hospitalizations, all while transitioning to value-based care arrangements.
Additional Information
Founded in 2020 and headquartered in Henderson, Nevada, P3 Health Partners uses data analytics and technology to proactively engage patients and manage chronic conditions. This approach not only emphasizes quality care but also focuses on cost-effective resource utilization, which is critical in today's healthcare landscape.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
320
CEO
Dr. Aric Coffman M.D.
Country
United States
IPO Year
2021
Website
p3hp.orgP3 Health Partners Inc. (PIII) Latest News & Analysis
Latest News
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners
29 days ago
Quick Summary
Trump's remark prompted a market shift on May 15, boosting micro-cap stocks with operational catalysts as traders moved into undervalued names.
Why It Matters
Trump's dismissive remark may signal investor sentiment shifts, leading to increased volatility in micro-cap stocks as traders seek opportunities in undervalued sectors with potential catalysts.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
P3 Health Partners Inc. (NASDAQ: PIII) reported $26 million in adjusted EBITDA for Q1 2026, marking a significant improvement due to contract restructuring and network concentration efforts.
Why It Matters
P3 Health Partners' $26 million adjusted EBITDA signals strong operational progress and effective strategy execution, potentially enhancing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
P3 Health Partners Inc. (PIII) held its Q1 2026 earnings call, discussing financial results and strategic updates. Further details can be found in the full transcript.
Why It Matters
P3 Health Partners' Q1 2026 earnings reveal financial performance and strategic direction, impacting stock valuation, investor sentiment, and future growth prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
P3 Health Partners Inc. (NASDAQ: PIII) will release its Q1 2026 financial results on May 14, 2026, followed by a conference call at 1:30 PM PT/4:30 PM ET.
Why It Matters
P3 Health Partners’ upcoming earnings release and conference call may impact stock performance, providing insights into financial health and growth potential, influencing investor sentiment and decisions.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
P3 Health Partners Inc. (PIII) held its Q4 2025 earnings call, discussing financial performance and future outlook. For detailed insights, refer to the transcript.
Why It Matters
The Q4 2025 earnings call for P3 Health Partners Inc. provides insights into financial performance and future guidance, influencing stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
P3 Health Partners Inc. (NASDAQ: PIII) reported its Q4 and full-year 2025 financial results, highlighting improved contract economics and provider alignment. 2026 guidance was also provided.
Why It Matters
P3 Health Partners' financial results and 2026 guidance indicate improved contract economics and operational discipline, suggesting potential for growth and stability, impacting investor sentiment positively.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PIII Stock
What is P3 Health Partners Inc.'s (PIII) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, P3 Health Partners Inc. (PIII) has a median price target of $14.00. The highest price target is $14.00 and the lowest is $14.00.
Is PIII stock a good investment in 2026?
According to current analyst ratings, PIII has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PIII stock?
Wall Street analysts predict PIII stock could reach $14.00 in the next 12 months. This represents a 19.8% increase from the current price of $11.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is P3 Health Partners Inc.'s business model?
The company operates a population health management model that partners with healthcare providers to enhance care coordination for Medicare-eligible patients. It generates revenue by offering support services that help clinicians improve patient outcomes and reduce hospitalizations, all while transitioning to value-based care arrangements.
What is the highest forecasted price for PIII P3 Health Partners Inc.?
The highest price target for PIII is $14.00 from Ryan Langston at TD Cowen, which represents a 19.8% increase from the current price of $11.69.
What is the lowest forecasted price for PIII P3 Health Partners Inc.?
The lowest price target for PIII is $14.00 from Ryan Langston at TD Cowen, which represents a 19.8% increase from the current price of $11.69.
What is the overall PIII consensus from analysts for P3 Health Partners Inc.?
The overall analyst consensus for PIII is neutral. Out of 3 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are PIII stock price projections?
Stock price projections, including those for P3 Health Partners Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 12:24 PM UTC